MR contrast agents in acute experimental cerebral ischemia: Potential adverse impacts on neurologic outcome and infarction size

Journal of Magnetic Resonance Imaging

Volumn 11, Issue 4, 2000, Pages 418-424

  Doerfler, Arnd ^a   Engelhorn, Tobias ^a   Heiland, Sabine ^b   Knauth, Michael ^b   Wanke, Isabel ^a   Forsting, Michael ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cerebral ischemia; Contrast agents; Magnetic resonance imaging; Middle cerebral artery occlusion

Indexed keywords

CONTRAST MEDIUM; GADODIAMIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOLUS INJECTION; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOSE RESPONSE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; STROKE;

ANIMALS; BASAL GANGLIA; BEHAVIOR, ANIMAL; BODY WEIGHT; BRAIN ISCHEMIA; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; GADOLINIUM DTPA; IMAGE ENHANCEMENT; INFARCTION, MIDDLE CEREBRAL ARTERY; IRON; MAGNETIC RESONANCE IMAGING; MALE; NEUROLOGIC EXAMINATION; OXIDES; RATS; RATS, WISTAR; REFERENCE VALUES; SURVIVAL RATE;

EID: 0034079740     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-2586(200004)11:4<418::AID-JMRI10>3.0.CO;2-W     Document Type: Article

References (35)

1. Camarata PJ, Heros RC, Latchaw RE. "Brain attack": the rationale for treating stroke as a medical emergency. Neurosurgery 1994;34: 144-158.
2. Brant-Zawadzki M, Pereira B, Weinstein P, et al. MR imaging of acute experimental ischemia in cats. AJNR 1986;7:7-11.
3. Rosen BR, Belliveau JW, Vevea JM, Brady TJ. Perfusion imaging with NMR contrast agents. Magn Reson Med 1990;14:249-265.
4. Kucharczyk J, Mintorovitch J, Asgari HS, Moseley M. Diffusion/ perfusion MR imaging of acute cerebral ischemia. Magn Reson Med 1991;19:311-315.
5. Warach S, Dashe JF, Edelman RR. Clinical outcome in ischemic stroke predicted by early diffusion-weighted and perfusion magnetic resonance imaging: a preliminary analysis. J Cereb Blood Flow Metab 1996;16:53-59.
6. Saini S, Stark DD, Hahn PF, Wittenberg J, Brady TJ, Ferrucci JT. Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system. Radiology 1987;162:211-216.
7. Stark DD, Weissleder R, Elizondo G, et al. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 1988;168:297-301.
8. Weissleder R, Stark DD, Engelstad BL, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR 1989;152:167-173.
9. Lancaster L, Bogdan AR, Kundel HL, McAffee B. Sodium MRI with coated magnetite: measurements of extravascular lung water in rats. Magn Reson Med 1991;19:96-104.
10. Kendall BE, Pullicino P. Intravascular contrast injection in ischemic lesions. II. Effect on prognosis. Neuroradiology 1980;19:241-243.
11. Doerfler A, Forsting M, Engelhorn T, et al. Are iodinated contrast agents detrimental in acute cerebral ischemia? An experimental study in rats. Radiology 1998;206:211-217.
12. Takahashi M, Tsutsui H, Murayama C, Miyazawa T, Fritz-Zieroth B. Neurotoxicity of gadolinium contrast agents for magnetic resonance imaging in rats with osmotically disrupted blood-brain barrier. Magn Reson Imaging 1996;14:619-23.
13. Koizumi J, Yoshida Y, Nakazawa T, et al. Experimental studies of ischemic brain edema: 1. A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jpn J Stroke 1986;8:1-8.
14. Harpur ES, Worah D, Hals PA, Holtz E, Furuhama K, Nomura H. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol 1993;28:28-43.
15. Normann PT, Hals PA. In vivo stability and excretion of gadodiamide (GdDTPA-BMA), a hydrophilic gadolinium complex used as a contrast enhancing agent for magnetic resonance imaging. Eur J Drug Metab Pharmacokinet 1995;20:307-313.
16. Menzies SA, Hoff JT, Betz LA. Middle cerebral artery occlusion in rats: a neurological and pathological evaluation of a reproducible model. Neurosurgery 1992;31:100-107.
17. Lin TN, He YY, Wu G, et al. Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke 1993;24:117-121.
18. Nagasawa H, Kogure K. Correlation between cerebral blood flow and histologic changes in a new rat model of middle cerebral artery occlusion. Stroke 1989;20:1037-1043.
19. Forsting M, Reith W, Schaebitz WR, et al. Decompressive craniectomy for cerebral infarction. An experimental study in rats. Stroke 1995;26:259-264.
20. Hong-Tai L, Saeed M, Wendland MF, Higgins CB. Cardiovascular responses after ionic and nonionic magnetic resonance contrast media in rats with acute myocardial infarction. Invest Radiol 1993; 28:11-19.
21. Rapoport SI, Thompson HK, Bidinger JM. Equi-osmolal opening of blood-brain barrier in the rabbit by different contrast media. Acta Radiol (Diagn) (Stockh) 1974;15:21-32.
22. Runge VM, Price AC, Wehr CJ, Atkinson JB, Tweedle MF. Contrast enhanced MRI. Evaluation of a canine model of osmotic blood-brain barrier disruption. Invest Radiol 1985;20:830-844.
23. Roman-Goldstein SM, Barnett P, McCormick CI, et al. Effects of Gd-DTPA after osmotic BBB disruption in a rodent model: toxicity and MR findings. J Comput Assist Tomogr 1994;18:731-736.
24. Tweedle MF. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 1992;27:2-6.
25. Neuwelt EA, Maravilla KR, Frenkel EP, Barnett P, Hill S, Moore RJ. Use of enhanced computed tomography to evaluate osmotic blood-brain barrier disruption. Neurosurgery 1980;6:49-56.
26. 3+ complexes used as magnetic resonance imaging contrast agent. Biomed Chromatogr 1998;12:21-26.
27. Ferrucci JT, Stark DD. Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years. AJR 1990;155:943-950.
28. Oksendahl AN, Hals PA. Biodistribution and toxicity of MR imaging contrast media. J Magn Reson Imaging 1993;3:157-165.
29. Hahn PF, Stark DD, Weissleder R, Elizondo G, Saini S, Ferrucci JT. Clinical application of superparamagnetic iron oxide to MR imaging of tissue perfusion in vascular liver tumors. Radiology 1990;174: 361-366.
30. Hamm B, Staks T, Taupitz M, et al. Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new super-paramagnetic iron oxide. J Magn Reson Imaging 1994;4:659-668.
31. Reimer P, Rummeny EJ, Daldrup HE, et al. Clinical results with Resovist: a phase 2 clinical trial. Radiology 1995;195:489-496.
32. Bellin MF, Zaim S, Auberton E, et al. Liver metastases: Safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. Radiology 1994;193:657-663.
33. Halavaara JT, Lamminen AE, Bondestam S, Standertskjöld-Nordenstam CG, Hamberg LM. Detection of focal liver lesions with superparamagnetic iron oxide: value of STIR and SE imaging. J Comput Assist Tomogr 1994;18:897-904.
34. Grangier C, Tourniaire J, Mentha G, et al. Enhancement of liver hemangiomas on T1-weighed MR SE images by superparamagnetic iron oxide particles. J Comput Assist Tomogr 1994;18:888-896.
35. Minematsu K, Fisher M, Li L, Sotak CH. Diffusion and perfusion MR imaging studies to evaluate a noncompetitive N-methyl-D-aspartate antagonist and reperfusion in experimental stroke in rats. Stroke 1993;24:2074-2081.